The critical path institutes approach to precompetitive sharing and advancing regulatory science

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 5, 2010, Pages 530-533

  Woosley, R L ^a   Myers, R T ^a   Goodsaid, F ^b  

^a CRITICAL PATH INSTITUTE   (United States)

^b Center for Drug Evaluation and Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

CLINICAL PATHWAY; COMPETITION; COMPUTER; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; KNOWLEDGE; NOTE; PRIORITY JOURNAL; SCIENCE; TECHNOLOGY; TELEVISION; UNITED STATES; ANIMAL; COOPERATION; DRUG DEVELOPMENT; ECONOMIC ASPECT; ECONOMICS; HUMAN; LEGAL ASPECT; METHODOLOGY; REVIEW;

ANIMALS; COOPERATIVE BEHAVIOR; CRITICAL PATHWAYS; DRUG DISCOVERY; DRUG INDUSTRY; ECONOMIC COMPETITION; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77951441171     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.27     Document Type: Note

References (16)

1. Grindley, P., Mowery, J.B. & Silverman, B.W. Sematech and collaborative research: lessons in the design of high-technology consortia. J. Policy Anal. Manage. 13, 723-758 (1994).
2. Hamilton, D.P. Sematech: techno-policy in action. Science 252, 23 (1991).
3. US Food and Drug Administration. Innovation or Stagnation: Challenges and Opportunity on the Critical Path to New Medical Products http://www.fda.gov/ ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/ucm077262. htm (2004).
4. US Food and Drug Administration. Innovation/Stagnation: Critical Path Opportunities List http://www.fda. gov/downloads/ScienceResearch/SpecialTopics/ CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM077258. pdf (March 2006).
5. Woodcock. J. & Woosley, R. The FDA critical path initiative and its influence on new drug development. Annu. Rev. Med. 59, 1-12 (2008).
6. Woosley, R.L. & Cossman, J. Drug development and the FDA's Critical Path Initiative. Clin. Pharmacol. Ther. 81, 129-133 (2007).
7. Hunter, A.J. The Innovative Medicines Initiative: a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients. Drug Discov. Today 13, 371-373 (2008).
8. Conry, T. et al. 18 big ideas to fix health care now. Reader's Digest 97-111 (November 2008).
9. US Food and Drug Administration. Memorandum of Understanding, Critical Path Institute and FDA. Fed. Reg. 70, 74823-74826 (2005).
10. Sacks, L.V. & Behrman, R.E. Developing new drugs for the treatment of drug-resistant tuberculosis: a regulatory perspective. Tuberculosis (Edinb) 88 (suppl. 1), S93-S100 (2008).
11. Cohen, M.H., Shen, Y.L., Keegan, P. & Pazdur, R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist (2009) 14, 1131-1138 (2008).
12. Goodsaid, F.M., Frueh, F.W. & Mattes, W. Strategic paths for biomarker qualification. Toxicology 245, 219-223 (2008).
13. Goodsaid, F., Frueh, F. & Mattes, W. The predictive safety testing consortium: a synthesis of the goals, challenges and accomplishments of the Critical Path. Drug Discov. Today: Technologies 4, 47-50 (2007).
14. Mattes, W.B. Public consortium efforts in toxicogenomics. Methods Mol. Biol. 460, 221-238 (2008).
15. Mattes, W.B. & Walker, E.G. Translational toxicology and the work of the predictive safety testing consortium. Clin. Pharmacol. Ther. 85, 327-330 (2009).
16. Romero, K., deMars, M., Frank, D., Anthony, M., Neville, J., Kirby, L. et al. The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases. Clin. Pharmacol. Ther. 86, 365-367 (2009).